Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

10/16/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020 , the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to
09/18/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Sept. 18, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 17, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000
08/21/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Aug. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 19, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,000 shares of
08/06/20	Coherus BioSciences Reports Second Quarter 2020 Financial Results – Second Quarter UDENYCA ® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million – REDWOOD CITY, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and

View All